About Us

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

Our team was built with deep expertise in genetic medicine development, allowing us to efficiently advance our programs from preclinical to clinical development. Our core capabilities in viral vector design and optimization and genetic medicine manufacturing give us a differentiated approach to developing gene medicines. Additionally, we are developing proprietary technology to potentially enable innovative gene therapy treatments whose expression can be turned on and off with an easily administered small molecule. We believe temporal control of genetic medicine products has the potential to transform the genetic medicine landscape.

Our state-of-the-art London manufacturing facility, completed in early 2018, was designed to meet global regulatory requirements, including the current good manufacturing practices (cGMP) required by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the U.S. Food and Drug Administration (FDA). The 29,000-square foot facility has the flexibility and capacity to produce sufficient product for all our clinical trials and will scale to commercial capacity. Our 150,000 square foot GMP manufacturing hub in Shannon, Ireland, operational in 2021, provides a flexible, scalable facility increasing capacity for clinical through commercial supply.  This facility also houses our GMP plasmid production, automated fill and finish and full QC laboratories.

Mission and Vision

Each day we work to improve the lives of patients through cutting-edge science designed to treat their specific disease. We believe each patient deserves the best treatment possible and with our highly flexible genetic medicine platform and manufacturing process, we believe we can deliver on that promise.

See Our Leadership Team